{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.093","value":"-0.09"},{"groupId":"OG001","spread":"0.099","value":"0.03"}]}],"title":"Change from baseline in BPI-SF worst pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.071","value":"-0.08"},{"groupId":"OG001","spread":"0.076","value":"-0.02"}]}],"title":"Change from baseline in BPI-SF pain severity score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.074","value":"0.01"},{"groupId":"OG001","spread":"0.079","value":"0.13"}]}],"title":"Change from baseline in BPI-SF pain interference score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"333"}],"units":"Participants"}],"description":"The BPI-SF is a validated, 15-item domain-specific instrument designed to assess the severity of pain and the impact/interference of pain on daily functions. BPI-SF worst pain, pain severity and pain interference score changes can be a minimum of -10 and a maximum of 10. A negative change from baseline value indicates improvement.","dispersionType":"Standard Error","groups":[{"description":"Patients receive oral treatment with olaparib 300mg twice daily in combination with abiraterone 1000mg once daily","id":"OG000","title":"Olaparib 300 mg bd + Abiraterone 1000 mg qd"},{"description":"Patients receive oral treatment with placebo twice daily in combination with abiraterone 1000mg once daily.","id":"OG001","title":"Placebo bd + Abiraterone 1000 mg qd"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Full Analysis Set (FAS), only patients with baseline assessment and at least one post treatment assessment are included in the analysis.","reportingStatus":"POSTED","timeFrame":"Assessed from date of randomisation to data cut off (DCO3): 12Oct2022 (Approx. 3 years 11 months)","title":"Brief Pain Inventory-Short Form (BPI-SF)","type":"SECONDARY","unitOfMeasure":"Score"}